Neothetics, Inc. (NEOT) Upgraded by ValuEngine to “Sell”

Neothetics, Inc. (NASDAQ:NEOT) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Tuesday, October 17th.

Shares of Neothetics (NASDAQ NEOT) traded down 3.08% during midday trading on Tuesday, reaching $1.26. 2,307,703 shares of the company traded hands. Neothetics has a 1-year low of $0.30 and a 1-year high of $2.63. The stock has a 50 day moving average price of $0.59 and a 200 day moving average price of $1.12. The firm’s market capitalization is $17.43 million.

Neothetics (NASDAQ:NEOT) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). Analysts expect that Neothetics will post ($0.61) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Neothetics, Inc. (NEOT) Upgraded by ValuEngine to “Sell”” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/neothetics-inc-neot-upgraded-by-valuengine-to-sell.html.

An institutional investor recently bought a new position in Neothetics stock. Virtu KCG Holdings LLC purchased a new position in Neothetics, Inc. (NASDAQ:NEOT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 278,219 shares of the biotechnology company’s stock, valued at approximately $150,000. Virtu KCG Holdings LLC owned about 2.01% of Neothetics at the end of the most recent quarter. Hedge funds and other institutional investors own 4.65% of the company’s stock.

Neothetics Company Profile

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply